Literature DB >> 10721103

Kynurenine and neopterin in chronic glomerulonephritis.

A Martinsons1, V Rudzite, V Groma, O Bratslavska, B Widner, D Fuchs.   

Abstract

The results of our clinical observations of 102 patients with chronic glomerulonephritis with normal renal function have shown that hyperkynureninemia in 22.5% of patients develops in cases of pyridoxal-5-phosphate deficiency (hyperkynureninemia after peroral L-tryptophan load), but in 14.8% of patients through the stimulation of the cellular immune system (hyperkynureninemia at fasting state, increase of serum neopterin concentration). In all 20 patients with chronic renal failure hyperkynureninemia develops due to decreased renal function (increased serum kynurenine, neopterin and creatinine concentrations). Therefore, L-tryptophan peroral loading test with the determination of serum concentration of kynurenine before and at 3rd hour after the load, as well as the detection of serum concentration of neopterin and creatinine are helpful for the differentiation of following pathologies in patients with chronic glomerulonephritis: pyridoxal-5-phosphate deficiency, cellular immune stimulation and chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10721103     DOI: 10.1007/978-1-4615-4709-9_72

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren's syndrome.

Authors:  M Pertovaara; A Raitala; H Uusitalo; J Pukander; H Helin; S S Oja; M Hurme
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 2.  The Kynurenine Pathway in Acute Kidney Injury and Chronic Kidney Disease.

Authors:  Hai Ning Wee; Jian-Jun Liu; Jianhong Ching; Jean-Paul Kovalik; Su Chi Lim
Journal:  Am J Nephrol       Date:  2021-11-09       Impact factor: 3.754

Review 3.  Kynurenine pathway in kidney diseases.

Authors:  Izabela Zakrocka; Wojciech Załuska
Journal:  Pharmacol Rep       Date:  2021-10-06       Impact factor: 3.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.